mobic and Adenomatous-Polyposis-Coli

mobic has been researched along with Adenomatous-Polyposis-Coli* in 3 studies

Other Studies

3 other study(ies) available for mobic and Adenomatous-Polyposis-Coli

ArticleYear
Efficacy of meloxicam in a patient with juvenile polyposis syndrome.
    Journal of pediatric gastroenterology and nutrition, 2009, Volume: 48, Issue:5

    Topics: Adenomatous Polyposis Coli; Child; Cyclooxygenase Inhibitors; Female; Humans; Meloxicam; Mutation, Missense; Thiazines; Thiazoles; Treatment Outcome

2009
Desmoid tumors respond to chemotherapy: defying the dogma in oncology.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-01, Volume: 24, Issue:1

    Topics: Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fibromatosis, Aggressive; Humans; Meloxicam; Thiazines; Thiazoles

2006
Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-01, Volume: 24, Issue:1

    Desmoid tumors are locally aggressive and can be fatal in familial adenomatous polyposis (FAP) patients if they are not suitable for surgery or radiation therapy. Here, we prospectively investigated the efficacy of a chemotherapeutic regimen involving doxorubicin (DOX) and dacarbazine (DTIC) for inoperable FAP-associated desmoid tumors.. From an initial group of 120 FAP patients, seven of the 11 individuals with symptomatic unresectable desmoid tumors that were unresponsive to conventional hormone therapy were enrolled onto this study. The general chemotherapy regimen comprised four or five cycles of DOX (20 mg/m2 daily) plus DTIC (150 mg/m2 daily) throughout 4 days of drip intravenous infusion (day 1 through 4) every 28 days, followed by the cyclooxygenase-2 inhibitor meloxicam (10 mg/m2). The primary end point was relapse-free survival. The secondary end points included toxicity, clinical improvement, and tumor regression according to computed tomography.. Significant tumor regression was observed clinically and radiologically in all seven patients. Three patients showed a complete response. The average progression-free survival period was 74.0 months (range, 32.5 to 107.5 months). Three patients showed grade 3 adverse events with no treatment-related mortality. All seven patients survived and remained without tumor progression. An adenomatous polyposis coli germline-mutation analysis revealed no mutations in the specified regions.. A chemotherapeutic regimen of DOX plus DTIC followed by meloxicam is an effective and safe treatment for FAP-associated desmoid tumors. This modality should be considered for use as first-line chemotherapy in symptomatic desmoid tumors that are unresponsive to conventional medical therapy, due to the absence of useful presymptomatic markers.

    Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Fibromatosis, Aggressive; Genes, APC; Germ-Line Mutation; Humans; Male; Meloxicam; Retrospective Studies; Thiazines; Thiazoles; Tomography, X-Ray Computed

2006